Introduction:
The development of gene-targeted drugs is one of the core research areas of Weili Health Technology Group, focusing on creating precise treatment solutions for major diseases such as cancer and cardiovascular diseases. The research and development of targeted drugs are based on in-depth studies of genetic mutations, protein structures, and signaling pathways of diseases, aiming to identify the fundamental causes of disease occurrence and progression. By specifically targeting these mutated genes or abnormally expressed proteins, targeted drugs can inhibit disease progression. Compared to traditional chemotherapy, targeted drugs have a lesser impact on normal cells, significantly reducing side effects and providing more efficient, low-toxicity treatment methods.
Weili is committed to developing personalized treatment plans tailored to the individual characteristics of different patients through advanced gene sequencing technology and big data analysis. By analyzing patients’ genetic profiles, pathogenic gene mutations can be identified, and specialized targeted drugs can be developed for these mutations. This precise medical approach greatly enhances treatment efficacy, reduces unnecessary treatment risks, and improves patients’ quality of life and survival rates.
Weili has established close collaborations with several top pharmaceutical companies and research institutions globally in the development of gene-targeted drugs, jointly developing multiple targeted drugs for various types of cancer, cardiovascular diseases, and pulmonary diseases. The company is leading advancements in precision medicine and aims to become a global leader in the field of gene-targeted drugs.
Core Highlights:
- Precision Targeting: Gene-targeted drugs specifically act on the pathogenic genes or abnormal proteins of cancer cells, avoiding harm to healthy cells.
- Personalized Treatment: By analyzing each patient’s mutations through gene sequencing, customized treatment plans are formulated to ensure maximum efficacy.
- Global Collaboration: Collaborating with international pharmaceutical companies such as Pfizer, Novartis, and Merck to jointly develop new targeted drugs.
- Broad Indications: Targeted drugs cover various types of cancer, cardiovascular diseases, and chronic diseases, significantly improving patients’ cure rates and quality of life.
Research Achievements:
- Crizotinib Combination Development: Crizotinib is a targeted drug used for treating non-small cell lung cancer, primarily aimed at patients with ALK gene mutations. Weili’s collaboratively developed combination drug has significantly extended the progression-free survival of ALK-positive lung cancer patients.
- Alectinib Combination Development: Alectinib targets ALK-positive non-small cell lung cancer patients by blocking ALK protein activity to inhibit cancer cell growth. Weili partnered with top pharmaceutical companies to develop combination formulations, reducing side effects and improving patient tolerance.
- Lorlatinib Combination Development: Lorlatinib is a targeted drug for ALK and ROS1 gene mutations, suitable for advanced or metastatic non-small cell lung cancer. Weili can accurately select patients suitable for this drug through its gene sequencing platform, significantly improving treatment outcomes.
- Brigatinib Combination Development: Brigatinib is a new ALK inhibitor specifically designed for patients who develop resistance to first-generation ALK-targeted drugs. Weili improved the drug’s effectiveness in refractory non-small cell lung cancer patients through collaborations with global pharmaceutical giants.
- Ceritinib Combination Development: This drug targets ALK-positive lung cancer patients and has been proven to significantly delay cancer progression. Weili ensures successful clinical application by screening suitable patient populations through genetic testing.
- Dabrafenib Combination Development: Dabrafenib primarily targets melanoma patients with BRAF gene mutations. Weili improved the efficacy of this targeted drug through collaborative development, extending patients’ survival.
- Erlotinib Combination Development: Erlotinib is a targeted drug for lung cancer with EGFR mutations, suitable for first-line treatment of advanced lung cancer patients. Weili’s drug development and clinical trials have allowed more patients to benefit, achieving significant treatment effects.
- Osimertinib Combination Development: Osimertinib is specifically for lung cancer patients with EGFR mutations and targets patients who develop resistance to first-generation EGFR inhibitors. Weili’s combination drug significantly reduces side effects and improves overall efficacy.
- Afatinib Combination Development: Afatinib is used to treat non-small cell lung cancer with EGFR and HER2 mutations. Weili’s research has improved the drug’s applicability in early and late-stage cancers.
- Savolitinib Combination Development: Savolitinib is a new MET inhibitor primarily used for lung cancer patients with MET mutations. Weili’s development of combination drugs has significantly enhanced the treatment effect, especially in advanced lung cancer patients.
- Amivantamab Combination Development: This drug is suitable for lung cancer patients with T790M mutations. Weili’s research team optimized the treatment plan to extend patients’ progression-free survival.
- Capmatinib Combination Development: Capmatinib is a targeted drug specifically for MET mutations. Weili’s combination drug development helps more patients receive precise treatment.
- Pralsetinib Combination Development: Pralsetinib is used for RET gene mutations in non-small cell lung cancer and thyroid cancer. Weili’s application of precision medicine helps clinicians select suitable patient populations, achieving excellent treatment results.
- Cabozantinib Combination Development: Cabozantinib is used to treat various cancer types, including kidney cancer, thyroid cancer, and liver cancer. Weili’s research has successfully improved its treatment efficacy and expanded the drug’s indications.
- Entrectinib Combination Development: Entrectinib is a targeted drug against NTRK fusion genes. Weili’s global collaborative development has shown significant efficacy in various tumor types.
Conclusion:
Through advanced gene sequencing and the development of precision-targeted drugs, Weili occupies a leading position in the global medical technology field. The development of gene-targeted drugs not only improves the cure rates for major diseases but also significantly reduces the side effects associated with traditional treatments, providing patients with safer and more effective treatment options. Weili will continue to promote the research and development of gene-targeted drugs in the global medical industry, bringing more personalized and precise treatment solutions to patients.